Janus face of Nrf2–HO-1 axis in cancer—Friend in chemoprevention, foe in anticancer therapy

Agnieszka Łoboda; Halina Waś; Alicja Józkowicz; Jozef Dulak

doi:10.1016/j.lungcan.2007.10.024

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2014

Regulation and Novel Action of Thymidine Phosphorylase in Non-Small Cell Lung Cancer: Crosstalk with Nrf2 and HO-1

Magdalena Tertil, Klaudia Skrzypek, Urszula Florczyk, Kazimierz Węglarczyk, Halina Waś, Guillaume Collet, Alan Guichard, Tomasz Gil, Jarosław Kużdżał, Alicja Józkowicz, Claudine Kiéda, Chantal Pichon, Jozef Dulak

Article2018

Simvastatin Treatment Upregulates HO‐1 in Patients with Abdominal Aortic Aneurysm but Independently of Nrf2

Aleksandra Piechota-Polańczyk, Aleksandra Kopacz, Damian Klóska, Branislav Zagrapan, Christoph Neumayer, Anna Grochot‐Przeczek, Ihor Huk, Christine Brostjan, Jozef Dulak, Alicja Józkowicz

Article2015

HO-1/CO system in tumor growth, angiogenesis and metabolism — Targeting HO-1 as an anti-tumor therapy

Agnieszka Łoboda, Alicja Józkowicz, Jozef Dulak

Article2016

Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism

Agnieszka Łoboda, Milena Damulewicz, Elżbieta Pyza, Alicja Józkowicz, Jozef Dulak

Article2017

Agrimonolide and Desmethylagrimonolide Induced HO-1 Expression in HepG2 Cells through Nrf2-Transduction and p38 Inactivation

Lei Chen, Hui Teng, Kalin Yanbo Zhang, Krystyna Skalicka‐Woźniak, Milen I. Georgiev, Jianbo Xiao